For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
KEY FINDINGS
The North America non-alcoholic steatohepatitis (NASH) biomarker market is projected to register a CAGR of 20.02%, over the forecast period of 2021 to 2028. The favorable reimbursements across the healthcare infrastructure, the anticipated launch of pipeline molecules, the early diagnosis of NASH, and the rising incidence of diabetes and obesity, is expected to fuel the region's market growth.
MARKET INSIGHTS
The North America non-alcoholic steatohepatitis (NASH) biomarker market growth is evaluated by assessing Canada and the United States. Non-alcoholic steatohepatitis (NASH) is the more critical form of non-alcoholic fatty liver disease. The term steatohepatitis entails fatty liver with inflammation or progressing damage similar to alcoholic liver disease. However, it occurs in individuals who either drink alcohol in moderation, or do not drink alcohol. Moreover, obesity and diabetes are the significant risk factors for non-alcoholic fatty liver disease, with their incidence continually rising in developed nations, like Canada.
Conversely, according to the Canadian Liver Foundation, non-alcoholic fatty liver disease (NAFLD) was estimated to be a very common condition across North America. It was also evaluated that nearly 20% and 4% of Canada's population has non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, respectively. While a simple fatty liver is a benign condition, NASH is typically associated with ongoing liver damage. Moreover, the disease can also lead to liver cancer, cirrhosis of the liver, as well as the need for a liver transplant. As a result, these factors are accredited to the North America non-alcoholic steatohepatitis (NASH) biomarker market growth, during the forecast years.
COMPETITIVE INSIGHTS
Some of the leading companies operating in the market are, Pfizer Inc, Novartis AG, Bristol-Myers Squibb, Gilead Sciences, etc.
Our report offerings include:
- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments